Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
First patient dosed in Merck’s Phase III PROCEADE-CRC-03 trial for mCRC
Merck KGaA (Merck) has dosed the first patient in its Phase III PROCEADE-CRC-03 trial, assessing the investigational anti‑carcinoembryonic antigen-related cell …
-
Adagio Medical seeks FDA PMA for ventricular ablation system
Adagio Medical has submitted a premarket approval (PMA) application to the US Food and Drug Administration (FDA) for its vCLAS …
-
Concept Life Sciences and OpenBench partner on drug discovery services
Concept Life Sciences has signed a strategic partnership with OpenBench to deliver success-based drug discovery services targeted at early-stage biotech …
-
OncoSil Medical secures TGA approval for pancreatic cancer device
OncoSil Medical has secured the Australian Therapeutic Goods Administration (TGA) approval for its OncoSil device, permitting its use in the …
-
HAYA Therapeutics doses first cohort in Phase I HTX-001 trial
HAYA Therapeutics has announced full enrolment and dosing of the first cohort in its Phase I clinical trial of HTX-001, …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Concept Life Sciences and OpenBench partner on drug discovery services
Concept Life Sciences has signed a strategic partnership with OpenBench to deliver success-based drug discovery services targeted at early-stage biotech …
-
OncoSil Medical secures TGA approval for pancreatic cancer device
OncoSil Medical has secured the Australian Therapeutic Goods Administration (TGA) approval for its OncoSil device, permitting its use in the …
-
HAYA Therapeutics doses first cohort in Phase I HTX-001 trial
HAYA Therapeutics has announced full enrolment and dosing of the first cohort in its Phase I clinical trial of HTX-001, …
-
BMS and Anthropic collaborate for Claude implementation
Bristol Myers Squibb (BMS) has signed a strategic agreement with Anthropic to implement its Claude platform across its global operations. The …
-
Sunrise Group secures FDA clearance for home sleep test
Sunrise Group has secured the US Food and Drug Administration (FDA) clearance for Sunrise Air, its latest rechargeable at-home sleep …
-
BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint
BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to …
-
SERB signs agreement to acquire Idefirix rights for $133.6m
SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix (imlifidase) from Hansa Biopharma for …
-
Hospital at home: the new model of modern care
Professor Rachid El Fatimy, dean of the Faculty of Medical Sciences and hospital general director at University Mohammed VI Polytechnic …
-
Boston Scientific invests $1.5bn for equity stake in MiRus
Boston Scientific has announced a $1.5bn investment to acquire approximately a 34% equity stake in MiRus, a company developing the …
-
First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial
Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody …
